Mpoudi-Etame Mireille, Tovar Sanchez Tamara, Bousmah Marwân-Al-Qays, Omgba Bassega Pierrette, Olinga Justin, Mimbe Eric, Foalem Michel, Chiep Camille, Edimo Serge, Varloteaux Marie, Pelloquin Raphaël, Lamare Nadine, Boyer Sylvie, Peeters Martine, Reynes Jacques, Calmy Alexandra, Hill Andrew, Delaporte Eric, Kouanfack Charles, Ayouba Ahidjo, Agholeng A, Butel Christelle, Granouillac B, Lacroix A, Leroy Sandrine, Serrano L, Kounfack C, Vidal Nicole, Fouda P, Mougnoutou R, Omgba V, Tchokonte Ngandé S, Ymele B, Donfack L, Kambi A, Epoupa Mpacko C, Fotso M, Moukoko R, Nké T, Akamba A, Lekelem S, Ngono S, Tongo Fotack S, Tanga M, Tsafack M, Bissek A, Ciaffi L, Lem S, Niba M, Camille N, Mpoudi-Ngole Eitel, Ebong E, Edoul Mbesse G, Tongo M, Huynh P, Maradan Gwenaëlle, Nishimwe Marie Libérée, Spire Bruno, Peytavin Gilles, Lê Mp, Yazdanpanah Yazdan, Diallo A, Fournier I, Montoyo A, Mercier N, Petrov?sanchez Ventizlava, Jean-Rassat J, Rekacewicz Claire, Perez Casas C. Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz–Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study. Open Forum Infectious Diseases. 2023;10(12):ofad582.  https://academic.oup.com/ofid/article/10/12/ofad582/7429393